Daiichi Sankyo Showcases DXd ADC Portfolio at ESMO 2023, Highlighting Potential New Standards of Care Across Multiple Cancers

Oct 17, 2023 18:20 CST Updated 18:20

Daiichi-Sankyo

Pharmaceutical R&D Developer

Demonstrating its ability to bring new standard treatments to patients with various types of cancer

Basking Ridge, New Jersey, October 17, 2023 /PRNewswire/ -- Daiichi Sankyo will present the latest clinical research advancements from its DXd antibody-drug conjugate (ADC) portfolio for the treatment of various types of cancer at the 2023 European Society for Medical Oncology (#ESMO23) Congress, taking place from October 20 to 24, 2023. Among more than 20 abstracts, three late-breaking abstracts, including two oral presentations in proffered paper sessions, highlight Daiichi Sankyo's leading position in bringing new standards of care to cancer patients.

On October 23, 2023 (Monday), the ESMO Congress Presidential Symposium will be held in a back-to-back format, focusing on highlighting Phase 3 studies.TROPION-Breast01AndTROPION-Lung01（LBA11AndLBA12) evaluated the efficacy of datopotamab deruxtecan (Dato-DXd) compared to chemotherapy in patients with metastatic HR-positive, HER2-low or negative breast cancer and advanced non-small cell lung cancer (NSCLC). These data will be released at a later ESMO press conference.

Daiichi-Sankyo will present other latest data through a small oral session, which will include the first report of a Phase 2 clinical study.DESTINY-PanTumor02（#LBA34) progression-free survival and overall survival results, the study aims to evaluate trastuzumab deruxtecan for injection (brand name: Enhertu^®) The efficacy in treating various HER2-expressing solid tumors, including biliary tract cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and other cancers.

Multiple small oral sessions will simultaneously present additional latest research data from the DXd ADC portfolio, including Phase 2 studies.HERTHENA-Lung01Exploratory analysis of the intracranial efficacy of patritumab deruxtecan (HER3-DXd) in treating patients with EGFR-mutated metastatic NSCLC in China, and the ongoing study of raludotatug deruxtecan (R-DXd) for patients with previously treated ovarian cancer.First-in-Human Phase 1 StudyThe latest data. Meanwhile, ongoing activities will also be presented in poster form.Phase 1/2 StudyLatest Clinical and Biomarker Results of Infinamab Deruxtecan (I-DXd) in Patients with Advanced Solid Tumors.

Ken Takeshita, MD, Head of Global R&D at Daiichi Sankyo, stated: "We continue to deliver innovative research results that demonstrate our industry-leading DXd ADC portfolio has the potential to change the standard of care for patients across multiple cancer types and treatment settings. Data from the first two pivotal studies, TROPION-Breast01 and TROPION-Lung01, in the Dato-DXd clinical development program highlight the transformative potential of the DXd ADC portfolio in treating certain HR-positive, HER2-low or negative metastatic breast cancers as well as advanced non-small cell lung cancer. Additionally, ongoing data from other studies involving T-DXd, HER3-DXd, R-DXd, and I-DXd support our continued application of DXd-ADC technology across different targets and tumor types with the aim of providing new treatment options for patients."

During the ESMO conference, Daiichi Sankyo will also present additional data on Dato-DXd, including data reported through two mini oral sessions, with the first report on the Phase 2 clinical study.TROPION-Lung05The latest data from a Phase 1b/2 study for the treatment of previously treated NSCLC patients with actionable gene mutations, and previously untreated triple-negative breast cancer patients.BEGONIAThe latest data.

Additional data on trastuzumab deruxtecan will be highlighted in small oral sessions, including a phase 2 clinical study conducted in patients with solid tumors harboring HER2-activating mutations.DESTINY-PanTumor01The main results and Phase 2 clinical studyDESTINY-Lung01AndDESTINY-Lung02Pooled analysis of data in HER2-mutated metastatic NSCLC patients with and without brain metastases. The Phase 3 clinical study will also be presented at the Preferred Paper Conference.DESTINY-Breast04Latest survival data in patients with HER2-low metastatic breast cancer, andDESTINY-Breast01、DESTINY-Breast02AndDESTINY-Breast03Exploratory Efficacy and Safety Summary Analysis in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases.

Meanwhile, Daiichi Sankyo will hold a virtual investor conference call on Tuesday, October 24, 2023, from 8:00-9:30 AM Eastern Time (Tuesday, October 24, 2023, from 9:00-10:30 PM Japan Standard Time). Executives from Daiichi Sankyo will provide an overview of the ESMO research data and answer questions during the call.

At the 2023 ESMO conference, Daiichi Sankyo will report the latest data summary of the DXd ADC product portfolio:

Report Title

Author

Abstract

Report Details

Datopotamab deruxtecan（Dato-DXd）

Breast Cancer

3Phase Clinical StudyTROPION-Breast01InDatopotamab deruxtecanCompared to chemotherapy for the treatment of patients who have previously been treated for inoperable or metastatic hormone receptor-positive,HER2Main Results of Negative Breast Cancer

A. Bardia

LBA11

Chairman's Symposium3

10Month23Day, Monday

4:30 – 4:42 pm CEST

10Month23Day, Monday
10:30 – 10:42 pm CST

Lung Cancer

3Phase Clinical StudyTROPION-Lung01InDatopotamab deruxtecan（Dato-DXd) Compared with docetaxel in the treatment of previously treated advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Research Results

A, Lisberg

LBA12

Chairman's Symposium3

10Month23Day, Monday

4:42 – 4:54 pm CEST

10Month23Day, Monday
10:42 – 10:54 pm CST

Enhertu (Trastuzumab Deruxtecan);T-DXd）

Pan-tumor

DESTINY-PanTumor02Study on Trastuzumab Deruxtecan (T-DXd) Treatment previously receivedHER2Primary Efficacy Analysis of Patients with Solid Tumors

F. Meric-

Bernstam

LBA34

Mini Oral Session

10Month23Day, Monday

4:40 – 4:45 pm CEST

10Month23Day, Monday
10:40 – 10:45 pm CST

Other key data abstracts to be presented at the 2023 ESMO conference:

Report Title

Author

Abstract

Report Details

Datopotamab deruxtecan（Dato-DXd）

Breast Cancer

1b/2Phase ResearchBEGONIACN Datopotamab deruxtecanCombined with Durvalumab for unresectable locally advanced/Latest Results in First-Line Treatment for Metastatic Triple-Negative Breast Cancer

P. Schmid

379MO

Small Oral Presentation Session

10Month22Day, Sunday

8:30 – 8:35 pm CEST

10Month23Day, Monday

00:30 – 00:35 am CST

Lung Cancer

TROPION-Lung05Under studydatopotamab deruxtecan（Dato-DXd) Treatment of non-small cell lung cancer with driver genomic mutations that have been previously treated

L. Paz-Ares

1314MO

Small Oral Presentation Session

10Month21Day, Saturday

9:30 – 9:35 am CEST

10Month21Day, Saturday
3:30 – 3:35 pm CST

3Phase ResearchTROPION-Lung07Chinadatopotamab deruxtecan（Dato-DXd）+Pembrolizumab with or without platinum-based chemotherapy as first-line treatmentPD-L1Advanced Expression/Metastatic Non-Small Cell Lung Cancer

I. Okamoto

1505TiP

Poster Presentation

10Month23Day, Monday

Enhertu (Trastuzumab Deruxtecan);T-DXd）

Breast Cancer

Random,3Phase Clinical StudyDESTINY-Breast04Comparison of Trastuzumab Biosimilar to Physician's Choice for TreatmentHER2Low expression, unresectable and/Latest Survival Data for Patients with Metastatic Breast Cancer

S. Modi

376O